Virtual Library
Start Your Search
S. Sarinc Ulasli
Author of
-
+
P3.03 - Poster Session with Presenters Present (ID 473)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Mesothelioma/Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies
- Presentations: 2
- Moderators:
- Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P3.03-023 - High Incidence of Somatic BAP1 Alterations in Sporadic Malignant Mesothelioma from Turkey (ID 5621)
14:30 - 14:30 | Author(s): S. Sarinc Ulasli
- Abstract
Background:
BRCA1-associated protein 1 (BAP1) gene is located at chromosome region 3p21.1, a genomic region that is deleted in several human malignancies, including approximately 30-60% of mesotheliomas(1). In this study, we retrospectively investigated BAP1 status in 41 unrelated patients with mesothelioma who had a history of environmental fibrous mineral exposure (erionite or asbestos). We have also reviewed histological tpe and clinical characteristics of the analyzed patients.
Methods:
A total of 41 malignant mesothelioma cases were reviewed histopathologically. Representative areas were selected and 4-mm-diameter tissue microarrays were composed from paraffin blocks. Immunohistochemistry (IHC) was performed on paraffin tissue sections prepared from microarrays with a monoclonal antibody against BAP1. Cases with loss of nuclear staining were considered as loss of BAP1 expression.
Results:
Satisfactory results were obtained in 37 patients (25 females, 12 males; mean age 56 yrs). Thirty-one cases were pleural, 5 cases were peritoneal and 1 case was paratesticular mesotheliomas. Histologically, 31 cases were epithelioid, and 6 cases were biphasic type. Overall all loss of BAP1 expression was 31/37 [83, 8 % ( 87, 1% pleural, 80% peritoneal, 0 paratesticular)]. Histologically, all biphasic types and 25/31 (80, 6%) epithelioid types showed BAP1 expression loss.
Conclusion:
Loss of BAP1 expression seems to be a frequent event in Turkish malignant mesotheliomas. However, in our small cohort, no significant correlation was found between tumor type and localization. We need to demonstrate both somatic and germ-like mutations in familial cases especially from erionite villages. References:1. Carbone M. BAP1 and Cancer. Nat Rev Cancer; 13: 153–159,1.2013.
-
+
P3.03-052 - Diagnostic Utility of Mesothelin, Osteopontin and Megakaryocyte Potentiation Factor in Turkish Patients with Malignant Mesothelioma (ID 4864)
14:30 - 14:30 | Author(s): S. Sarinc Ulasli
- Abstract
Background:
Malignant mesothelioma (MM) is an agressive tumor with poor prognosis, thus early assessment is important. We investigated the presence of mesothelin, osteopontin and megakaryocyte potentiation factor (MPF) levels in both sera and pleural effusions of MM patients and compared to the lung cancer, other malignancy, exudative and transudative effusions.
Methods:
Patients were enrolled into 5 study groups as demonstrated in table 1. Serum and pleural mesothelin, osteopontin and MPF levels of study groups were measured with enzyme-linked immunosorbent assay and compared with using convenient statistical methods.
Results:
Figure 1 Figure 2 Mesothelin and osteopontin levels in both sera and pleural effusions were found to be statistically different among groups (Table 1). Pleural mesothelin and osteopontin levels were significant parameters to differentiate MM from the other groups (p=0.0001; p=0.002 respectively). When cut off value of pleural mesothelin level was set at 169.6ng/mL, sensitivity was 71.4 % and specificity was 88% for MM. When cut off value of pleural osteopontin level was set at 521.25ng/mL, sensitivity was 64.3% and specificity was 80% for MM (Figure 1). Pleural but not sera MPF level of MM patients was significantly higher than patients with lung cancer (p=0.021).
Conclusion:
Mesothelin, osteopontin and MPF levels can be used as diagnostic bio-markers to detect MM.
